Latest news with #VeraTherapeutics
Reuters
2 days ago
- Business
- Reuters
Otsuka's kidney disease therapy trial results heat up battle with rival Vera
June 6 (Reuters) - Otsuka's (4578.T), opens new tab experimental therapy for a potentially life-threatening kidney disease more than halved severe levels of protein in the urine of patients, intensifying the battle for an effective new treatment with rival Vera Therapeutics (VERA.O), opens new tab. The Japan-based company said on Friday its therapy, sibeprenlimab, cut proteinuria levels by 51.2% in patients with Immunoglobulin A Nephropathy, also known as Berger's disease, at nine months in a late-stage trial. The data comes just days after Vera said its drug, atacicept, reduced protein levels in patients' urine by 46%, compared with a 7% reduction with a placebo, meeting the main goal of a 428-patient late-stage study. Shares of the U.S.-based drug developer slid 31% to $20.89. Analysts, however, said that though data from Otsuka's sibeprenlimab might look superior, it was unlikely that doctors would interpret it that way. The difference between the two datasets is not too clinically diverse to affect demand for Vera's drug, said Jefferies analyst Farzin Haque. Berger's disease causes abnormal protein buildup in the kidneys and could eventually lead to the organ's failure. Analysts have estimated the U.S. market for its treatments could be worth as much as $10 billion. Otsuka has already applied for the FDA's accelerated approval for its therapy to treat the disease. However, its sales would largely depend on whether the treatment can improve kidney function, analysts said. Even if the drug gains accelerated approval, Otsuka said it plans to study whether it can preserve the organ's ability to filter toxins from blood, measured as the glomerular filtration rate (eGFR). "The magnitude of the protein reduction should translate into eGFR preservation down the line, because ultimately that's what patients are going to be asking for," Dana Rizk, the trial's investigator and a professor of medicine at the University of Alabama in Birmingham, told Reuters. The study is expected to be completed in early 2026.
Business Insider
3 days ago
- Business
- Business Insider
Vera Therapeutics (VERA) Gets a Buy from Evercore ISI
In a report released today, Liisa Bayko from Evercore ISI reiterated a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $75.00. The company's shares opened today at $21.27. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Bayko is a 4-star analyst with an average return of 7.6% and a 44.00% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Altimmune, Vertex Pharmaceuticals, and Intellia Therapeutics. Currently, the analyst consensus on Vera Therapeutics is a Strong Buy with an average price target of $67.36, implying a 216.76% upside from current levels. In a report released today, TD Cowen also reiterated a Buy rating on the stock with a $60.00 price target.
Business Insider
3 days ago
- Business
- Business Insider
Vera Therapeutics (VERA) Receives a Buy from Raymond James
Raymond James analyst Ryan Deschner reiterated a Buy rating on Vera Therapeutics (VERA – Research Report) today and set a price target of $73.00. The company's shares opened today at $21.27. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Deschner covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, ARS Pharmaceuticals, and Trevi Therapeutics. According to TipRanks, Deschner has an average return of 18.4% and a 59.26% success rate on recommended stocks. Currently, the analyst consensus on Vera Therapeutics is a Strong Buy with an average price target of $67.36, a 216.76% upside from current levels. In a report released today, TD Cowen also reiterated a Buy rating on the stock with a $60.00 price target.
Business Insider
3 days ago
- Business
- Business Insider
Guggenheim Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
Guggenheim analyst Vamil Divan reiterated a Buy rating on Vera Therapeutics (VERA – Research Report) today and set a price target of $65.00. The company's shares opened today at $21.27. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Divan covers the Healthcare sector, focusing on stocks such as Insmed, Johnson & Johnson, and Pfizer. According to TipRanks, Divan has an average return of 4.6% and a 51.02% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vera Therapeutics with a $67.36 average price target, implying a 216.76% upside from current levels. In a report released today, TD Cowen also reiterated a Buy rating on the stock with a $60.00 price target.
Yahoo
6 days ago
- Business
- Yahoo
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami Beach, FL from June 9 – 11, 2025. The management team will also participate in one-on-one investor meetings. Fireside Chat Details:Date: Wednesday, June 11, 2025 Time: 3:15pm EDTWebcast: A replay of the event will be available for 90 days and can be accessed by visiting the 'Investor Calendar' section of the Vera Therapeutics website. About VeraVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit For more information, please contact: Investor Contact:Joyce AllaireLifeSci Advisors212-915-2569jallaire@ Media Contact:Debra CharlesworthVera Therapeutics415-854-8051corporatecommunications@
